FLX-787 / Decoy Therapeutics - LARVOL DELTA

Flex-201: A Multicenter, Randomized, Blinded Study to Evaluate the Efficacy and Tolerability of FLX-787 in MS. (ACTRIMS Forum 2017) - "While repeat dosing of FLX-787 is efficacious in NLC clinical studies, a parallel study design may minimize the potential for carry-over effects. Given the beneficial characteristic of no systemic exposure of the FLX-787 parent drug, we believe that the risk of drug-drug interactions or systemic effects seen with other MS agents should be less likely to occur with FLX-787. Results in several human studies to date suggest that repeat dosing of FLX-787 may cause a general increase in the inhibitory tone of spinal circuits to limit cramps, spasms and potentially spasticity in those living with MS."

Clinical • HEOR • Biosimilar • Multiple Sclerosis